Discovery and initial characterization of the paullones, a novel class of smallmolecule inhibitors of cyclin-dependent kinases

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2566-2569

  Zaharevitz, Daniel W ^a   Gussio, Rick ^a   Leost, Maryse ^b   Senderowicz, Adrian M ^a   Lahusen, Tyler ^a   Kunick, Conrad ^c   Meijer, Laurent ^b   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CNRS   (France)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; PAULLONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PATTERN RECOGNITION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN FAMILY; TRANSCRIPTION REGULATION;

ALGORITHMS; BENZAZEPINES; CELL CYCLE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; INDOLES; MODELS, CHEMICAL; PIPERIDINES;

EID: 0033152122     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Morgan, D. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol., 13: 261-291, 1997.
2. Dunphy, W. G. (ed.). Cell cycle control. Methods in Enzymology, Vol. 283, 678 p. New York: Academic Press, 1997.
3. Meijer, L., Guidel, S., and Philippe, M. (eds.). Progress in Cell Cycle Research. Vol. 3, 321 pp. New York: Plenum Publishing Corp., 1997.
4. Kamb, A. Cyclin-dependent kinase inhibitors and human cancer. Curr. Top. Microbiol. Immunol., 227: 139-148, 1998.
5. Meijer, L., and Kim, S-H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol., 283: 113-128, 1997.
6. Walker, D. H. Small-molecule inhibitors of cyclin-dependent kinases: molecular tools and potential therapeutics. Curr. Top. Microbiol. Immunol., 227: 149-165, 1998.
7. Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J-G., Moulinoux, J-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, cdk5. Eur. J. Biochem., 243: 527-536, 1997.
8. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-1999, 1998.
9. Paull, K. D., Hamel, E., and Malspeis, L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: W. O. Foye (ed.), Cancer Chemotherapeutic Agents, pp. 9-45. Washington, DC: American Chemical Society Books, 1995.
10. Paull, K. D., Lin, C. M., Malspeis, L., and Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res., 52: 3892-3900, 1992.
11. Gharehbaghi, K., Paull, K. D., Kelley, J. A., Barchi, J. U., Jr., Marquez, V. E., Cooney, D. A, Monks, A., Scudiero, D., Kohn, K., and Jayaram, H. N. Cytotoxicity and characterization of an active metabolite of benzamide ribose, a novel inhibitor of IMP dehydrogenase. Int. J. Cancer, 56: 892-899, 1994.
12. Cleaveland, E. S., Zaharevitz, D. W., Kelley, J. A., Paull, K., Cooney, D. A., and Ford, H., Jr. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar. Biochem. Biophys. Res. Commun., 223: 654-659, 1996.
13. Kohlhagen, G., Paull, K. D., Cushman, M., Nagafuji, P., and Pommier, Y. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol., 54: 50-58, 1998.
14. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 201: 589-595, 1994.
15. Sedlacek, H. H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., and Sausville, E. Flavopiridol (L86-8275. NSC-649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 9: 1143-1168, 1996.
16. Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L., and Worland, P. J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
17. Schulze-Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., and Kim, S-H. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopenteyladenine. Proteins, 22: 378-391, 1995.
18. De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Stmad, M., and Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogs: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem., 243: 518-526, 1997.
19. Kunick, C. Synthese von 7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-onen und 6,11-dihydro-thieno-[3′,2′:2,3]azepino[4,5-b]indol-5(4H)-on. Arch. Pharm. (Weinheim), 325: 297-299, 1992.
20. Gray, N. S., Wodicka, L., Thunnissen, A-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., Kim, S-H., Lockhart, D. J., and Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (Washington DC), 281: 533-538, 1998.